Bristol-myers Squibb Company

United States of America


 
Total IP 4,897
Total IP incl. subs 5,446 (+ 554 for subs)
Total IP Rank # 227
IP Activity Score 4/5.0    2,248
IP Activity Rank # 299
IP AS incl. subs 3.7/5.0    2,287
Stock Symbol
ISIN US1101221083
Market Cap. 119,099M  (USD)
Industry Drug Manufacturers - Major
Sector Healthcare
Dominant Nice Class Pharmaceutical, veterinary and s...

Patents

Trademarks

2,082 320
219 300
1,648 0
328
 
Last Patent 2025 - Combination therapy for colorect...
First Patent 1975 - Cephalosporin esters
Last Trademark 2025 - LIBHAYLS
First Trademark 1951 - LOWILA

Subsidiaries

31 subsidiaries with IP (516 patents, 38 trademarks)

86 subsidiaries without IP

 Register for free to unlock the subsidiary list

Industry (Nice Classification)

Latest Inventions, Goods, Services

2025 G/S Pharmaceutical and biological preparations for human use.
G/S Pharmaceutical and biological preparations for human use.
G/S Pharmaceutical and biological preparations for human use.
G/S Pharmaceutical preparations for the treatment and prevention of cancer
G/S Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases,...
Invention Tim-3 antagonists for the treatment and diagnosis of cancers. Provided herein are methods for tr...
Invention Methods of producing recombinant proteins. In certain embodiments, this disclosure provides nove...
Invention Compounds and their use for treatment of hemoglobinopathies. Disclosed herein are compounds and ...
Invention Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors. Provided are meth...
Invention Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an...
Invention Methods of treating urothelial carcinoma using an anti-pd-1 antibody. This disclosure provides a...
Invention Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti...
Invention Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment. This inven...
Invention Methods to manipulate quality attributes of polypeptides produced in cho cells. In accordance wi...
Invention Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody...
Invention Cytokine profiling analysis. This invention relates to methods for predicting a prognosis of a p...
Invention Methods of treating a tumor using an anti-pd-1 antibody. This disclosure provides a method for t...
Invention Indicating differences in and reconciling data stored in disparate data storage devices. A metho...
2024 Invention Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use. Disclosed herein ...
Invention Substituted heterocyclic compounds. There are disclosed compounds of the following formula I: ...
Invention Substituted phenyl oxazolone compounds. Disclosed are compounds of Formula (I): Disclosed are ...
Invention Machine-learning models for prognosing outcomes for hypertrophic cardiomyopathy (hcm). A computer...
Invention Machine-learning models for prognosing outcomes for hypertrophic cardiomyopathy (hcm). A compute...
Invention Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof. The...
Invention 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1...
Invention 2-(4-(2-(7,8-dimethyl-[l,2,4jtriazolo[l,5-a]pyridin-6-yl)-3-isopropyl- lh-indol-5-yl)piperid!n-l-...
Invention Antisense oligonucleotides targeting alpha-synuclein and uses thereof. The present disclosure re...
Invention Antibodies binding to vista at acidic ph. The present application relates to antibodies specific...
Invention Modulators of bcl6 as ligand directed degraders. Provided herein are compounds and compositions t...
Invention Methods of treatment with a myosin inhibitor using protein levels. Methods of treatment with a my...
Invention Ubiquitin specific processing protease 1 (usp1) compounds. Compounds having the following formula...
Invention Ubiquitin specific processing protease 1 (usp1) compounds. Compounds having the following formul...
Invention Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof. Th...
Invention Treatment of renal cell carcinoma. This disclosure provides methods for treating a subject affli...
Invention Gspt1 compounds and methods of use of the compounds. Provided herein are compounds of Formula I:,...
Invention Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma. Prov...
Invention Treatment of hodgkin lymphoma using an anti-pd-1 antibody. This disclosure provides to methods f...
Invention Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)pheny...
Invention Antibodies against tim3 and uses thereof. Provided herein are antibodies, or antigen binding por...
Invention Macrocyclic peptides useful as modulators of tnf alpha. Disclosed are macrocyclic peptide compou...
Invention Kras inhibitors. The present disclosure provides KRAS inhibitors. Methods of treating cancers us...
2023 Invention Combination therapy for colorectal carcinoma. The invention provides a method of treating a colo...
Invention Substituted imidazopyridinyl compounds useful as inhibitors of tlr9. Disclosed are compounds of ...
Invention Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9. Disclosed are compounds ...
2022 Invention Macrocyclic immunomodulators. In accordance with the present disclosure, macrocyclic compounds h...
Invention Cyclic peptide immunomodulators. The present disclosure provides novel macrocyclic peptides whic...